Table 1.

Baseline Patient Characteristic

Table 1. Baseline Patient Characteristics and Treatment Dosage Information
Dose level	Dose of Veliparib	Age	Sex	Disease Stage	ECOG PS	BRCA Mutation	Founder
0–2A		58 (41–71)	10 M 7 F	III–IV	0–1	N/A	N/A
0	20 mg BID	70	M	IV	0	BRCA1: 185delAG	Founder (AJ)
0		62	M	IV	1	BRCA2: 6174delT	Founder (AJ)
0		66	M	IV	1
1	40 mg BID	60	M	IV	1
1		64	M	IV	1	BRCA2: 6174delT	Founder (AJ)
1		57	M	III	1	Unknown	Unknown
2	80 mg BID	70	F	IV	1	BRCA1: 2800delAA	N
2		56	F	IV	1	BRCA1: 187delAG	Founder (AJ)
2		58	M	IV	1	BRCA2: 6174delT	Founder (AJ)
2		51	F	IV	0	BRCA2: c.8177A>G	N
2		55	M	IV	1
2		50	F	IV	1	BRCA1: 5385insC	Founder (AJ)
2A	80 mg BID cont	71	F	III	0
2A		58	M	IV	1
2A		50	F	IV	1	BRCA2: D281N(1069G>A)	N
2A		70	M	IV	1
2A		41	F	IV	1

Fifteen patients had stage IV disease and 2 patients had stage III. One patient in dose level 1 had an unknown BRCA status, but was included in the BRCA− group. Gemcitabine is fixed at 600 mg/m² IV and cisplatin is fixed at 25 mg/m² IV.